Healthcare Industry News: Adaptive Radiation Therapy
News Release - November 6, 2006
Calypso(R) Medical and Philips Announce Advancements in Product CollaborationPHILADELPHIA, Nov. 6 (HSMN NewsFeed) -- CalypsoŽ Medical announces product development advancement on strategic collaboration efforts with Philips at the 48th Annual American Society for Therapeutic Radiology and Oncology (ASTRO) meeting, November 5-8.
The CalypsoŽ 4D Localization System is designed to provide an objective, continuous, real-time method to setup radiation treatment and monitor the patient during radiation delivery without adding ionizing radiation. "Our collaboration with Philips Radiation Oncology Systems business is focused on advancing radiation treatment options," said Eric R. Meier, Calypso Medical's president and CEO. "The prostate motion data from our clinical study confirms the importance of knowing the exact location of the prostate at treatment setup and to monitor the prostate motion during treatment delivery moment to moment. Integrating continuous, real-time monitoring data with Philips' treatment planning software systems builds on our collaboration agreement to co-develop product offerings that advance planning and treatment delivery techniques. Plans are underway to bring truly Adaptive Radiation Therapy techniques to the clinical community through our collaboration," adds Meier.
The Radiation Oncology Systems business of Philips expects to provide enhancements to its treatment planning systems with target localization data from the Calypso 4D Localization System as a result of this collaboration. "That Calypso Medical technology can provide objective knowledge to manage motion for prostate therapy is significant. Static imaging, regardless of when it's performed, is simply not enough," explains Keith Tipton, general manager of Philips' Radiation Oncology Systems group. He adds, "The joint product development efforts between Calypso Medical and PROS will undoubtedly advance prostate therapy. And in addition, we're very keen to apply what we learn from prostate motion management to other cancer disease sites where motion plays a critical role."
About CalypsoŽ Medical
Calypso Medical Technologies, Inc. ("Calypso") is a Seattle, WA based privately held medical device company. Calypso addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (BeaconŽ electromagnetic transponders) to accurately, objectively and continuously pinpoint the location of tumors in real-time. In addition, the CalypsoŽ 4D Localization System's non-ionizing electromagnetic guidance has the potential to improve work flow efficiency and treatment room utilization. The product is FDA 510(k) cleared for use in the prostate application only. http://www.calypsomedical.com.
About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in healthcare, lifestyle and technology, delivering products, services and solutions through the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 126,000 employees in more than 60 countries worldwide. With sales of $37.7 billion (EUR 30.4 billion) in 2005, the company is a market leader in medical diagnostic imaging and patient monitoring systems, energy efficient lighting solutions, personal care and home appliances, as well as consumer electronics. News from Philips is located at http://www.philips.com/newscenter.
Source: Calypso Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.